We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Epigenomics AG Begins Trading on OTCQX® PR Newswire NEW YORK, Jan. 10, 2014 NEW YORK, Jan. 10, 2014 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, today announced the results of a survey conducted at europacolon’s first European CRC...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostics company, reports that Dr. Uri Ladabaum, Associate Professor in the Department of...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnosis company, today announced the signing of a supply agreement with Life Technologies Corporation, a...
Epigenomics AG (FWB:ECX), the cancer diagnosis company, today announced the appointment of Noel Doheny as the new Chief Executive Officer (CEO) of its subsidiary Epigenomics...
Epigenomics AG (FWB:ECX), the cancer molecular diagnostics company, and QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that the companies have entered...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostic company, today announced that it has concluded the feasibility phase in the development of an...
Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer diagnostics company, and Predictive Biosciences, a commercial stage, fully-integrated developer of novel molecular...
Epigenomics AG, the cancer diagnostics company, announced that new data obtained in a clinical study with the Company’s proprietary Septin9 biomarker for the blood-based...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions